---
title: "Beyond Metabolically Healthy Obesity"
id: "jama-pediatrics-0-beyond-metabolically-healthy-obesity"
canonical_url: "https://medichelpline.com/clinical-feed/jama-pediatrics-0-beyond-metabolically-healthy-obesity"
content_type: "clinical_feed_article"
specialty: "Pediatrics"
source_name: "JAMA Pediatrics"
source_url: "https://jamanetwork.com/journals/jamapediatrics/fullarticle/2847890"
published_at: "2026-04-20T00:00:00.000Z"
evidence_level: "Journal Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Beyond Metabolically Healthy Obesity
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/jama-pediatrics-0-beyond-metabolically-healthy-obesity
- **Specialty:** [Pediatrics](https://medichelpline.com/clinical-feed/pediatrics.md)
- **Primary Source:** JAMA Pediatrics
- **Source URL:** [Original Journal Publication](https://jamanetwork.com/journals/jamapediatrics/fullarticle/2847890)
- **Published At:** 2026-04-20T00:00:00.000Z
- **Evidence Rating:** Journal Feed
## Executive GIST (TL;DR)
In JAMA Pediatrics, Putri and colleagues report long-term cardiometabolic outcomes among 7275 children who initiated obesity treatment in Sweden and were followed up through young adulthood, alongside more than 35 000 matched peers from the general population. Nearly half of the children with obesity met criteria for metabolically healthy obesity at baseline, defined by the absence of elevated blood pressure, impaired fasting glycemia, elevated transaminases as a marker of hepatic involvement, elevated triglycerides, and low high-density lipoprotein cholesterol. However, by age 30 years, children classified as having metabolically healthy obesity experienced substantially higher cumulative incidences of type 2 diabetes, hypertension, and dyslipidemia than their peers without obesity. Although their risks were lower than those of children with metabolically unhealthy obesity, the contrast with the general population was striking. Importantly, even a modest reduction in body mass index z score during treatment was associated with meaningful reductions in cardiometabolic risk in both the metabolically healthy and unhealthy groups. These findings challenge the assumption that the absence of metabolic abnormalities in childhood identifies a group at low long-term risk.
## Clinical Analysis & Structured Key Points
In JAMA Pediatrics, Putri and colleagues report long-term cardiometabolic outcomes among 7275 children who initiated obesity treatment in Sweden and were followed up through young adulthood, alongside more than 35 000 matched peers from the general population. Nearly half of the children with obesity met criteria for metabolically healthy obesity at baseline, defined by the absence of elevated blood pressure, impaired fasting glycemia, elevated transaminases as a marker of hepatic involvement, elevated triglycerides, and low high-density lipoprotein cholesterol. However, by age 30 years, children classified as having metabolically healthy obesity experienced substantially higher cumulative incidences of type 2 diabetes, hypertension, and dyslipidemia than their peers without obesity. Although their risks were lower than those of children with metabolically unhealthy obesity, the contrast with the general population was striking. Importantly, even a modest reduction in body mass index z score during treatment was associated with meaningful reductions in cardiometabolic risk in both the metabolically healthy and unhealthy groups. These findings challenge the assumption that the absence of metabolic abnormalities in childhood identifies a group at low long-term risk.
## Related Clinical Research

- [New ACC/AHA Guidance on Cardiovascular Care for Tactical Athletes](https://medichelpline.com/clinical-feed/stat-news-1-tactical-athletes-get-new-guidance-for-cardiovascular-fitness.md)
- [Framework for Assessing Cardiovascular Risk and Fitness for Duty in Tactical Athletes](https://medichelpline.com/clinical-feed/aha-news-0-new-guidance-introduces-framework-for-assessing-cardiovascular-risk-and-fitness.md)
- [Left ventricular hypertrophy and brain atrophy in type 2 diabetes: findings from the D2 cohort](https://medichelpline.com/clinical-feed/medrxiv-0-left-ventricular-hypertrophy-brain-atrophy-and-cognitive-decline-in-type-2.md)
- [GLP-1 Receptor Agonist Start Does Not Reduce Anti-VEGF Injection Frequency in Diabetic Macular Ede](https://medichelpline.com/clinical-feed/medrxiv-15-glp-1-receptor-agonist-initiation-and-anti-vegf-treatment-frequency-in-diabetic.md)
- [ENDO 2026: Progress and Resilience in Endocrinology and Obesity Care](https://medichelpline.com/clinical-feed/endocrine-news-0-endo-2026-progress-and-resilience.md)

## Navigation
- [← Back to Pediatrics Feed](https://medichelpline.com/clinical-feed/pediatrics.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.